SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors, despite their beneficial effects on blood glucose, blood pressure, and CVD risk [33, 34], may induce euglycaemic DKA, even doubling the risk compared with DPP4 inhibitors [5, 35], which is an important factor considering the occurrence of DKA in T2D.